SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001358403-17-000093
Filing Date
2017-06-15
Accepted
2017-06-15 16:36:56
Documents
3
Period of Report
2017-06-14

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_149755900162646.html 4  
1 FORM 4 wf-form4_149755900162646.xml 4 3906
2 LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS poastephendavis7-13x2015.htm EX-24 3305
3 POWER OF ATTORNEY ex-24.htm EX-24 3160
  Complete submission text file 0001358403-17-000093.txt   11856
Mailing Address NEUROGEN CORP 35 NORTHEAST INDUSTRIAL RD BRANFORD CT 06405
Business Address
DAVIS STEPHEN (Reporting) CIK: 0001131146 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36783 | Film No.: 17913891

Mailing Address 2130 WEST HOLCOMBE BOULEVARD SUITE 800 HOUSTON TX 77030
Business Address 2130 WEST HOLCOMBE BOULEVARD SUITE 800 HOUSTON TX 77030 (832) 384-1100
BELLICUM PHARMACEUTICALS, INC (Issuer) CIK: 0001358403 (see all company filings)

IRS No.: 201450200 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations